November 27, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")

We refer to our letter dated August 18, 2026 and November 11, 2026 in relation to share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited ("IQGEN-X"). The acquisition of remaining 1,24,493 equity shares representing 10.99% of the issued and paid-up equity share capital of IQGEN-X by the Company has been completed and closing under the share purchase agreement is now complete. With this acquisition, the Company has acquired a 76% stake in IQGEN-X.

This is for your information and records

Thanking You,

Your Sincerely,

For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

RUDALF JOSEPH CORRIEA
Digitally signed by RUDALF JOSEPH CORRIEA
Date: 2026.11.27 18:00:29 +05'30'

Rudalf Corriea
Company Secretary & Compliance Officer